ABSI|EPS $0.84|Rev $2.8 M|Net Loss $29.6M
Company Overview
Absci Corporation is a clinical-stage biopharmaceutical company that utilizes generative AI to advance breakthrough therapeutics.
Key Financial Figures
For the full year ended December 31, 2025, Absci reported total revenue of $2.8 million. The company’s basic and diluted net loss per share (EPS) for the full year 2025 was $(0.84).
Additional Financial Insights
Research and development expenses for 2025 were $81.4 million, driven primarily by the external preclinical and clinical advancement of internal programs. As of December 31, 2025, Absci maintained $144.3 million in cash, cash equivalents, and marketable securities. The company expects these existing capital resources to be sufficient to fund operations into the first half of 2028
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.